Noticias de KOD

Mercado

Noticias del mercado

Últimas noticias sobre KOD — 235 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: KOD ✕ 235 resultados
15/10/2026 KOD_US — Timothy Sykes ES ← EN
Las acciones de KOD se disparan a medida que el ensayo DAYBREAK reescribe las expectativas biotecnológicas

Kodiak Sciences Inc surged as pivotal clinical trial progress fueled investor optimism, and its stocks have been trading up by 8.56 percent. Key Takeaways Shares of Kodiak Sciences (KOD) exploded between roughly 100% and 190% after Zenkuda and tabirafusp-ted hit Phase 3 endpoints in wet age-related

15/10/2026 KOD_US — ad-hoc-news.de
HC Wainwright raises target for Kodiak Sciences stock to USD 126.00

Second-quarter loss reached USD 1.05 per share. Kodiak Sciences stock costs EUR 77.04 on October 15,

15/10/2026 KOD_US — Timothy Sykes
KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations

Kodiak Sciences Inc subió a medida que el progreso de los ensayos clínicos fundamentales alimentó el optimismo de los inversores, y sus acciones han subido un 8,56 por ciento. Conclusiones clave Las acciones de Kodiak Sciences (KOD) se dispararon entre aproximadamente un 100% y un 190% después de que Zenkuda y tabirafusp-ted alcanzaran los criterios de valoración de la fase 3 en relación con la edad húmeda.

10/10/2026 KOD_US — Seeking Alpha
Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow

2026-10-10. The following slide deck was published by Kodiak Sciences Inc.

08/10/2026 KOD_US — AD HOC NEWS
Wall Street Zen upgrades Kodiak Sciences stock to Sell

Loss reached USD 65.6 million in second quarter of 2026. Kodiak Sciences stock costs EUR 81.04 on Oc

07/10/2026 KOD_US — Yahoo Finance
Kodiak Sciences Inc. (KOD) Interactive Stock Chart

Interactive Chart for Kodiak Sciences Inc. (KOD), analyze all the data with a huge range of indicators.

07/10/2026 KOD_US — Yahoo Finance
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).

07/10/2026 KOD_US — Yahoo Finance
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).

07/10/2026 KOD_US — Stock Titan
First scientific results from a trial of two treatments for age-related vision loss will be presented Oct. 9.

DAYBREAK met its primary endpoint for both treatments, with non-inferior vision gains vs. aflibercept at Year 1; GLOW2 and APEX data are scheduled.

Página 4 de 12